GC 021109
Alternative Names: GC-021109Latest Information Update: 28 Apr 2021
At a glance
- Originator Tufts University
- Developer GliaCure
- Class Anti-inflammatories; Antidementias; Small molecules
- Mechanism of Action Glial cell modulators; Purinoceptor P2Y6 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (PO)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in USA (PO)
- 18 Apr 2019 GC 021109 is still in phase I trials for Alzheimer's disease in USA (PO)